旨在研究“根治性”绿光膀胱肿瘤光选择汽化术 (RPVBT) 与术后化疗联合治疗单发、直径 < 3 cm、T2 期肌层浸润性膀胱癌 (MIBC) 患者的生存结果。38 名单发膀胱肿瘤患者，< 3 cm，T2期膀胱癌采用RPVBT联合化疗治疗，纳入RPVBT组。为了比较生存结果的差异，80 名 Ta/T1 膀胱癌患者和 30 名 T2 膀胱癌患者被纳入对照。 80例Ta/T1膀胱癌患者接受GreenLight膀胱肿瘤光选择性汽化术（PVBT），30例T2膀胱癌患者接受根治性膀胱切除术（RC）联合盆腔淋巴结清扫术（PLND）。记录肿瘤复发和死亡情况，绘制无复发生存（RFS）和总生存（OS）曲线，比较RPVBT组与对照组的生存差异。RPVBT组与对照组的合并症或生活习惯无显着差异。对照组。失血量 [RPVBT：20 (IQR10, 20) 对比 RC：100 (IQR90, 150) mL] 和术后住院时间 [RPVBT：5.5 (IQR5, 6)，对比 RC：10 (IQR8, 12) 天] RPVBT组显着低于RC组。尿路感染 [RPVBT：6 (15.8%) vs. PVBT：14 (17.5%)] 和膀胱刺激症状 [RPVBT：11 (28.9%) vs. PVBT：23 (28.8%)] 是最常见的短期症状RPVBT组的并发症发生情况，RPVBT与PVBT组之间无统计学差异。对于手术后纳入的患者，生存终点的中位随访时间为 22 (16, 27) 个月。 RPVBT 组中 12、24 和 36 个月时肿瘤复发的结果分别为 2 例（5.3%）、3 例（7.9%）和 5 例（13.2%）患者，其中 13 例（16.3%）和 3 例（10%）患者PVBT 组和 RC 组在 36 个月时出现复发。三组之间没有显着差异（P = 0.778）。此外，Kaplan-Meier生存分析显示三组之间的RFS（P = 0.791）和OS（P = 0.689）无统计学差异。我们的研究结果表明，RPVBT联合化疗是一种简单可行的治疗选择，并发症较少，且安全可靠。单发、< 3 cm、T2 期膀胱癌患者获得满意的生存结果。© 2024。作者。

To investigate the survival outcome of "radical" GreenLight photoselective vaporization of bladder tumor (RPVBT) in conjunction with postoperative chemotherapy for patients with single, < 3 cm in diameter, T2 stage muscle invasive bladder cancer (MIBC).Thirty-eight patients with single, < 3 cm, T2 stage bladder cancer were treated with RPVBT combined with chemotherapy and were included in the RPVBT group. To compare the differences in survival outcome, 80 patients with Ta/T1 bladder cancer and 30 patients with T2 bladder cancer were included as controls. The 80 patients with Ta/T1 bladder cancer underwent GreenLight photoselective vaporization of bladder tumors(PVBT), while 30 patients with T2 bladder cancer underwent radical cystectomy (RC) combined with pelvic lymph node dissection (PLND). Tumor recurrence and death were recorded, and recurrence-free survival (RFS) and overall survival (OS) curves were plotted to compare the survival difference between the RPVBT and control groups.No significant differences were observed in comorbidities or living habits between the RPVBT and control groups. Blood loss [RPVBT: 20 (IQR10, 20) vs. RC: 100 (IQR90, 150) mL] and postoperative hospital stay [RPVBT: 5.5 (IQR5, 6), vs. RC: 10 (IQR8, 12) days] in the RPVBT group were significantly lower than that in the RC group. Urinary tract infection [RPVBT: 6 (15.8%) vs. PVBT: 14 (17.5%)] and bladder irritation sign [RPVBT: 11 (28.9%) vs. PVBT: 23 (28.8%) ] were the most common short-term complications in the RPVBT group, with no statistical difference between the RPVBT and PVBT group. The median follow-up time for survival endpoints was 22 (16, 27) months for the included patients after surgery. The outcomes of tumor recurrence at 12, 24, and 36 months were 2 (5.3%), 3 (7.9%), and 5 (13.2%) patients in the RPVBT groups, 13 (16.3%) and 3 (10%) patients experienced recurrence in the PVBT and RC groups at 36 months. No significant differences were noted among the three groups (P = 0.778). Additionally, Kaplan-Meier survival analysis revealed no statistically significant differences in RFS (P = 0.791) and OS (P = 0.689) among the three groups.Our findings indicate that RPVBT combined with chemotherapy is a simple and feasible treatment option with fewer complications and satisfactory survival outcomes in patients with single, < 3 cm, T2 stage bladder cancer.© 2024. The Author(s).